Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

High prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer.

Bannon SA, Montiel MF, Goldstein JB, Dong W, Mork ME, Borras E, Hasanov M, Varadhachary GR, Maitra A, Katz MHG, Feng L, Futreal PA, Fogelman DR, Vilar E, McAllister F.

Cancer Prev Res (Phila). 2018 Oct 1. pii: canprevres.0014.2018. doi: 10.1158/1940-6207.CAPR-18-0014. [Epub ahead of print]

PMID:
30274973
2.

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.

Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M.

J Hematol Oncol. 2018 May 30;11(1):71. doi: 10.1186/s13045-018-0616-2.

3.

Medical oncology and pancreatic cancer: what the radiologist needs to know.

Fogelman DR, Varadhachary G.

Abdom Radiol (NY). 2018 Feb;43(2):383-392. doi: 10.1007/s00261-017-1432-9.

PMID:
29285600
4.

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience.

Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, Fogelman DR, Meric-Bernstam F, Piha-Paul SA.

Oncotarget. 2017 Aug 3;8(50):87163-87173. doi: 10.18632/oncotarget.19897. eCollection 2017 Oct 20.

5.

FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma.

Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A.

Oncotarget. 2017 Jun 13;8(24):39268-39279. doi: 10.18632/oncotarget.16848.

6.

Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.

Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S.

Clin Cancer Res. 2017 Aug 1;23(15):4146-4154. doi: 10.1158/1078-0432.CCR-16-3138. Epub 2017 Mar 9.

7.

Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer.

Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S.

PLoS One. 2017 Mar 7;12(3):e0173345. doi: 10.1371/journal.pone.0173345. eCollection 2017. Erratum in: PLoS One. 2017 May 17;12 (5):e0178275.

8.

A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients.

Fogelman DR, Morris J, Xiao L, Hassan M, Vadhan S, Overman M, Javle S, Shroff R, Varadhachary G, Wolff R, Vence L, Maitra A, Cleeland C, Wang XS.

Support Care Cancer. 2017 Jun;25(6):1809-1817. doi: 10.1007/s00520-016-3553-z. Epub 2017 Jan 22.

PMID:
28111717
9.

Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer.

Wang XS, Shi Q, Dougherty PM, Eng C, Mendoza TR, Williams LA, Fogelman DR, Cleeland CS.

Oncology. 2016;90(3):127-35. doi: 10.1159/000443377. Epub 2016 Feb 17.

10.

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.

Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K.

Drug Des Devel Ther. 2015 Sep 3;9:5075-86. doi: 10.2147/DDDT.S84177. eCollection 2015.

11.

Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer.

Shah MS, Fogelman DR, Raghav KP, Heymach JV, Tran HT, Jiang ZQ, Kopetz S, Daniel CR.

Cancer. 2015 Sep 1;121(17):2968-75. doi: 10.1002/cncr.29440. Epub 2015 May 14.

12.

Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.

Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH.

Lancet Oncol. 2015 Jun;16(6):695-703. doi: 10.1016/S1470-2045(15)70136-1. Epub 2015 May 5.

13.

Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?

Fogelman DR, Holmes H, Mohammed K, Katz MH, Prado CM, Lieffers J, Garg N, Varadhachary GR, Shroff R, Overman MJ, Garrett C, Wolff RA, Javle M.

J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):307-13. doi: 10.1007/s13539-014-0145-y. Epub 2014 Apr 17.

14.

Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab.

Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH.

Pancreas. 2014 Apr;43(3):343-9. doi: 10.1097/MPA.0000000000000095.

15.

The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.

Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, Varadhachary G, Wolff RA, Abbruzzese JL, Fogelman DR.

Invest New Drugs. 2013 Oct;31(5):1375-83. doi: 10.1007/s10637-013-9967-2. Epub 2013 May 4.

PMID:
23645398
16.

Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.

Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Fogelman DR, Crane CH, Balachandran A, Katz MH.

Ann Surg Oncol. 2012 Jun;19(6):2045-53. doi: 10.1245/s10434-011-2211-4. Epub 2012 Jan 19.

PMID:
22258816
17.

The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.

Dakik HK, Moskovic DJ, Carlson PJ, Tamm EP, Qiao W, Wolff RA, Abbruzzese JL, Fogelman DR.

Cancer Chemother Pharmacol. 2012 Feb;69(2):425-30. doi: 10.1007/s00280-011-1705-x. Epub 2011 Aug 18.

18.

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL.

Anticancer Res. 2011 Apr;31(4):1417-20.

PMID:
21508395
19.

Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury.

Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S.

Clin Colorectal Cancer. 2009 Oct;8(4):225-30. doi: 10.3816/CCC.2009.n.038.

PMID:
19822514
20.

Emerging drugs for colorectal cancer.

Fogelman DR, Kopetz S, Eng C.

Expert Opin Emerg Drugs. 2008 Dec;13(4):629-42. doi: 10.1517/14728210802544575 . Review.

PMID:
19046131
21.

The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.

Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot J.

Cancer Chemother Pharmacol. 2008 Jan;61(1):167-75. Epub 2007 Apr 18. Erratum in: Cancer Chemother Pharmacol. 2008 Jan;61(1):177.

PMID:
17440727
22.

Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy.

Fine RL, Shah SS, Moulton TA, Yu IR, Fogelman DR, Richardson M, Burris HA, Samuels BL, Assanasen C, Gorroochurn P, Hibshoosh H, Orjuela M, Garvin J, Goldman FD, Dubovsky D, Walterhouse D, Halligan G.

Cancer Chemother Pharmacol. 2007 Mar;59(4):429-37. Epub 2006 Aug 3.

PMID:
16896931
23.

The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX.

Fogelman DR, Chen J, Chabot JA, Allendorf JD, Schrope BA, Ennis RD, Schreibman SM, Fine RL.

Surg Oncol Clin N Am. 2004 Oct;13(4):711-35, x. Review.

PMID:
15350944
24.

Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer.

Frucht H, Stevens PD, Fogelman DR, Verna EC, Chen J, Chabot JA, Fine RL.

Curr Treat Options Gastroenterol. 2004 Oct;7(5):343-354.

PMID:
15345205

Supplemental Content

Loading ...
Support Center